Neurocrine adds a Parkinson’s drug to its late-stage pipeline in $145M deal
With one drug under review at the FDA, Neurocrine Biosciences $NBIX is following up with a deal to in-license a new therapy it can add to the late-stage pipeline.
The San Diego-based biotech turned to Portugal’s Bial for North American rights to Ongentys (opicapone), a once-daily COMT inhibitor approved in Europe as an adjunctive therapy for Parkinson’s disease.
Bial is getting $30 million upfront and up to $115 million in milestones in the deal. And once the deal is done, Neurocrine execs plan to sit down with the FDA and talk about a new drug application.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
